Mood disorders, including depression, are the most common comorbid conditions in individuals with epilepsy, but the cause remains unclear, according to a latest study by researchers at Columbia University Mailman School of Public Health and Rutgers University. The findings suggest that there may be a shared genetic susceptibility to these conditions, expressed only in people with focal epilepsy, in which seizures start in one part of the brain. Results of the study are published in the journal Epilepsia.
[Photo: Dr. Ruth Ottman]
“While the comorbidity of mood disorders and epilepsy has been known for a long time, mood disorders are under-recognized and under-treated among people with epilepsy, noted Dr. Ruth Ottman, professor of epidemiology at the Mailman School of Public Health and deputy director for research at the G.H. Sergievsky Center of Columbia University.
In the study, which included 60 families containing multiple individuals with epilepsy, the lifetime prevalence of mood disorders was significantly increased in people with focal epilepsy but not in people with generalized epilepsy. Prevalence of mood disorders was also increased in people with epilepsy who had relatives with focal epilepsy. Among family members who did not have epilepsy, the lifetime prevalence of mood disorders appeared to be higher than in the general population, but this result did not reach statistical significance.
Taken together, the findings are consistent with the hypothesis of shared genetic susceptibility to epilepsy and mood disorders, but the effect may be restricted to focal epilepsy and may only be expressed in individuals whose epilepsy susceptibility-related genes are ‘penetrant’ — that is, in people who have epilepsy, according to the authors.
In the U.S., about 2.3 million adults and more than 450,000 children and adolescents have epilepsy, and anyone can develop the disorder. In 2015, an estimated 16.1 million adults at least 18 years old in the U.S. had at least one major depressive episode in the past year, according to federal figures.
“This study points to the importance of screening and treatment,” Dr. Ottman said. “Additional research is needed to identify specific genes that raise risk for both disorders, and may lead to development of promising new treatments.”
The study was funded by National Human Genome Research Institute, P50 HG007257; Epilepsy Foundation; National Institute of Neurological Disorders and Stroke, K23 NS054981; and National Institutes of Health, R01 NS078419, P50 HG007257.